Takeda Pharmaceutical Co - ADR

Takeda Pharmaceutical Co - ADR

TAK

Get informed when a big investor buys or sells

+ Follow
Market Cap$50.27B
Close$

Compare to Similar Companies

P/E RatioDividendsReturn on EquityPrice-to-SalesDebt-to-Equity
Takeda Pharmaceutical Co - ADRTakeda Pharmaceutical Co - ADR41.43.94%2%-0.6

Earnings Call Q4 2025

May 13, 2026 - AI Summary

FY25 headline + momentum into 2026 - Takeda delivered core revenue ~JPY 4.5T (−2.6% CER) and core operating profit (core OP) ~JPY 1.17T (−0.9% CER), with results showing resilience despite VYVANSE generic erosion. - Cash flow remained strong: operating cash flow ~JPY 1T+ and adjusted free cash flow ~JPY 684.5B (after $1.2B upfront to Innovent for the oncology partnership). - Surprise/good: core EPS grew ~3.1% at CER (reported EPS JPY 122) aided by a favorable tax position tied to pipeline progress (deferred tax asset recoverability reassessment).
2026 guidance (key numbers) — growth by launching new assets, but margins pressured - Revenue guidance: low single-digit % decline at CER, but reported revenue expected to rise ~+3% (to ~JPY 4.64T on actual FX). - Profit guidance: core OP decline 5–8% at CER, reflecting “growth investment” behind launches + R&D; core EPS expected to decline in the mid-teens (tax effect comparison). - Free cash flow guidance: JPY 650–750B, supporting capital flexibility and shareholder returns.
Three major launch “engine” (what investors should watch most) - Takeda expects three potentially blockbuster launches in the next 12 months (timing windows): - oveporexton (narcolepsy type 1; orexin agonist): priority review granted (FDA); U.S. launch 2H26; additional international filings/launch prep for Japan/China. - rusfertide (polycythemia vera; hepcidin mimetic): FDA priority review; launch 2H26; commercial focus on disease awareness + access. - zasocitinib (oral psoriasis): commercialization planned 1H27; positioning relies on rapid, durable skin clearance and once-daily oral dosing without fasting. - Opportunity: these launches are positioned as new growth drivers that should shift Takeda’s revenue profile away from mature portfolio pressures.

Exclusive for Stockcircle Pro members

Sign upSign Up
$31.78

Current Fair Value

99.7% upside

Undervalued by 99.7% based on the discounted cash flow analysis.

Share Statistics

Market cap$50.27 Billion
Enterprise Value$4.36 Trillion
Dividend Yield$0.62 (3.94%)
Earnings per Share$63.91
Beta0.09
Outstanding Shares3,124,984,000

Return

Return on Equity2.47%ROE
Return on Assets1.24%
Return on Invested Capital5.19%

Valuation & Multiples

P/E Ratio41.41P/E Ratio
PEG-54.49PEG
Price to Sales0.01Price to Sales
Price to Book Ratio0.01Price to Book Ratio
Enterprise Value to Revenue0.96
Enterprise Value to EBIT6.42
Enterprise Value to Net Income22
Total Debt to Enterprise1.13
Debt to Equity0.63Debt to Equity

Revenue Sources

No data

Insider Trades

Last Earnings Call

Report Date
May 14, 2026
EPS Estimate
$0.01
Average shareholder expectation
Revenue Estimate
$7.25 B
Average shareholder expectation

Next Earnings Call

Expected Date
July 29, 2026
EPS Estimate
$0.22
Average shareholder expectation
Revenue Estimate
$7.39 B
Average shareholder expectation

Institutional Put/Call Ratio

Market sentiment based on institutional option activity.

Put/Call Ratio0.0449▼ 3.43%
Total Calls1,632,500▼ 20.59%
Total Puts73,300▼ 55.00%

Institutional Ownership

Holdings and activity of institutional investors.

Ownership %3.11%▲ 0.46%
Total Invested$1.82B▲ 39.22%
Investors Holding364▲ 11.00%

ESG Score

No data

About Takeda Pharmaceutical Co

CEO: Christophe Weber

Relevant Senate Committees

Finance

This powerful committee controls taxation, trade, and entitlement spending, including Medicare pricing. These policy areas directly impact a pharmaceutical company's profitability (tax policy), market access (trade), and revenue streams from major payers (Medicare drug pricing).

Appropriations

This committee allocates discretionary federal spending. Its subcommittees determine the precise funding for health agencies (FDA, NIH) and federal healthcare programs (e.g., VA), directly affecting regulatory resources, research grants, and government purchases of pharmaceuticals.

Health, Education, Labor, and Pensions

This committee directly regulates the FDA and NIH, driving drug approval oversight and scientific research funding. These functions are absolutely critical to the core business and stock performance of a pharmaceutical company.

Judiciary

This committee oversees antitrust laws and intellectual property (patents), both of which are foundational to the pharmaceutical industry's business model, M&A activities, and competitive landscape.

Veterans' Affairs

The Department of Veterans Affairs is a major purchaser and provider of pharmaceuticals. This committee's funding decisions directly impact government healthcare contractors, including pharmaceutical companies that supply the VA healthcare system.